Medical Director, Oncology R&D – Lung & Head/Neck

Gsk; Stevenage; On-site; GBP 110,000 - 180,000; Full time

Job summary

GSK is seeking a Medical Director, Oncology Clinical Development – Lung & Head/Neck Cancers to lead medical monitoring, safety oversight, and data interpretation within the clinical programme team. The role is initially based in Stevenage, with plans to relocate to Cambridge early in 2029.

The physician will partner with senior scientists and cross-functional teams to ensure patient safety, regulatory compliance, and scientifically sound study delivery across complex oncology programmes.

Qualifications

• MD (or equivalent medical degree) with oncology expertise and trial experience.
• Experience in medical monitoring, safety review, and data interpretation.
• Ability to lead cross-functional teams and interact with regulators.

Responsibilities

• Serve as the physician within the clinical programme team, providing medical expertise across study design, conduct, safety oversight, and data interpretation.
• Lead medical monitoring activities for clinical studies, ensuring patient safety, clinical integrity, and regulatory compliance.
• Interpret clinical and safety data to inform study- and programme-level decisions, collaborating with cross-functional teams.
• Contribute to protocol development, ICF review, and regulatory documentation with CDL guidance.
• Engage with investigators and KEEs to support study conduct and external representation of the programme.
• Support regulatory interactions and scientific communications from a physician perspective.

Skills

Oncology Clinical Development

Medical Monitoring

Clinical Data Interpretation

Cross-functional Leadership

Regulatory Affairs

Study Design

Education

MD or equivalent medical degree

Job description

GSK is seeking a Medical Director, Oncology Clinical Development – Lung & Head/Neck Cancers to lead medical monitoring, safety oversight, and data interpretation within the clinical programme team. The role is initially based in Stevenage, with plans to relocate to Cambridge early in 2029.

The physician will partner with senior scientists and cross-functional teams to ensure patient safety, regulatory compliance, and scientifically sound study delivery across complex oncology programmes.